277 related articles for article (PubMed ID: 36819490)
21. Actin-Like Protein 8 Promotes the Progression of Triple-Negative Breast Cancer via Activating PI3K/AKT/mTOR Pathway.
Fan S; Yan S; Yang Y; Shang J; Hao M
Onco Targets Ther; 2021; 14():2463-2473. PubMed ID: 33883901
[TBL] [Abstract][Full Text] [Related]
22. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
23. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
[TBL] [Abstract][Full Text] [Related]
24. Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signaling pathways.
Liu L; Yan J; Cao Y; Yan Y; Shen X; Yu B; Tao L; Wang S
Oncol Lett; 2021 Jan; 21(1):70. PubMed ID: 33365081
[TBL] [Abstract][Full Text] [Related]
25. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
26. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
27. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
[TBL] [Abstract][Full Text] [Related]
28. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
29. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
30. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
31. Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.
Gao Y; Feng Y; Liu S; Zhang Y; Wang J; Qin T; Chen P; Li K
Cancer Med; 2023 Jul; 12(14):15337-15349. PubMed ID: 37350549
[TBL] [Abstract][Full Text] [Related]
32. The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer.
Zheng W; Sun G; Li Z; Wu F; Sun G; Cao H; Zhou J; Ma Y
Front Surg; 2022; 9():895982. PubMed ID: 35495754
[TBL] [Abstract][Full Text] [Related]
33. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
Cheng W; Liu D; Guo M; Li H; Wang Q
Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
35. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.
Shao B; Li CW; Lim SO; Sun L; Lai YJ; Hou J; Liu C; Chang CW; Qiu Y; Hsu JM; Chan LC; Zha Z; Li H; Hung MC
Am J Cancer Res; 2018; 8(9):1837-1846. PubMed ID: 30323975
[TBL] [Abstract][Full Text] [Related]
36. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
37. Radix Tetrastigma Extracts Enhance the Chemosensitivity in Triple-Negative Breast Cancer Via Inhibiting PI3K/Akt/mTOR-Mediated Autophagy.
Zhang S; Cui T; Duan Y; Zhang H; Wang B; Chen H; Ni J; Shen Y; Xiao-Ai Lv
Clin Breast Cancer; 2022 Feb; 22(2):89-97. PubMed ID: 34535390
[TBL] [Abstract][Full Text] [Related]
38. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
[TBL] [Abstract][Full Text] [Related]
39. Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer.
Ono H; Horinaka M; Sukeno M; Morita M; Yasuda S; Nishimoto E; Konishi E; Sakai T
Cancer Sci; 2021 Oct; 112(10):4166-4175. PubMed ID: 34288272
[TBL] [Abstract][Full Text] [Related]
40. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
